CAJ | 학술논문

目的:探讨晚期非小细胞肺癌(NSCLC)患者应用吉非替尼治疗的效果及毒副反应.方法:回顾2003年1月～2008年12月应用吉非替尼治疗的晚期NSCLC有随访资料的患者56例,其中一线治疗5例,二线或三线治疗51例,对其疗效、毒副反应及生存期进行分析.结果:全组56例,PR 12例,占21.4%;SD 20例,占35.7%;PD 24例,占42.9%.疾病控制率(PR+SD)为57.1%. 获PR的12例患者中位缓解时间为6个月(3～78个月);获SD的20例患者中位稳定时间为4个月(2～24个月).吉非替尼治疗获疾病控制者(PR+SD)与无效者(PD)相比,其中位生存时间明显延长(P=0.000).痤疮样皮疹发生率占66.1%,多为轻、中度性. 腹泻多为轻度.结论:吉非替尼治疗晚期NSCLC的疗效较好,毒副反应较轻,可以耐受.
목적:탐토만기비소세포폐암(NSCLC)환자응용길비체니치료적효과급독부반응.방법:회고2003년1월～2008년12월응용길비체니치료적만기NSCLC유수방자료적환자56례,기중일선치료5례,이선혹삼선치료51례,대기료효、독부반응급생존기진행분석.결과:전조56례,PR 12례,점21.4%;SD 20례,점35.7%;PD 24례,점42.9%.질병공제솔(PR+SD)위57.1%. 획PR적12례환자중위완해시간위6개월(3～78개월);획SD적20례환자중위은정시간위4개월(2～24개월).길비체니치료획질병공제자(PR+SD)여무효자(PD)상비,기중위생존시간명현연장(P=0.000).좌창양피진발생솔점66.1%,다위경、중도성. 복사다위경도.결론:길비체니치료만기NSCLC적료효교호,독부반응교경,가이내수.
Objective:To explore the efficacy, side effects, toxicity and survival time of gefitinib for ITT patients with advavced non-small cell lung cancer(NSCLC). Methods:Retrospective analysis of the efficacy, side effects and toxicity and survival conditions for gefitinib in treatment of the 56 cases with advanced NSCLC and followed-up from January 2003 to December 2008. Results:Among of 56 cases with NSCLC in the treatment of gefitinib, partial response (PR) accounted for 21.4%; stable disease (SD) accounted for 35.7%; disease control rate(PR+SD)accounted for 57.1%. Median response time in 12 cases with PR was 6 months (range, 3-78); however, median response time in 20 cases with SD was 4 months (range, 2-24). Median survival time and overall survival were significantly improved on response patients (PR or SD) in comparison to nonresponse (PD) for gefitinib (P<0.001). Skin rash accounted for 66.1%. There was no significant relationship between rash severity degree and response. Diarrhea was mild and self-limited. Conclusion:This clinical observation suggested that gefetinib in treatment of patients with advanced NSCLC has better efficacy and well-tolerated toxicity.